H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on WHWK stock, giving a Hold rating on October 24.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Robert Burns has given his Hold rating due to a combination of factors surrounding Whitehawk Therapeutics. The company’s recent financial results showed a higher net loss per share than previously estimated, indicating some financial challenges. Despite having a substantial cash reserve that could support operations into 2028, the company faces uncertainties with its upcoming clinical trials and drug development.
Additionally, while there are several anticipated catalysts, such as IND submissions for new drug candidates, these are still in early stages and not yet included in the company’s valuation due to the lack of clinical efficacy data. Furthermore, potential risks such as disappointing market uptake of their existing product, FYARRO, and challenges in developing it for other cancer indications contribute to the cautious outlook. As a result, Burns maintains a Neutral stance, opting to reassess the situation as the company’s lead candidates progress further in development.
In another report released on October 24, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $2.50 price target.